Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist

Lancet. 1991 May 4;337(8749):1062-3. doi: 10.1016/0140-6736(91)91709-4.

Abstract

In a double-blind study ten asthmatic patients with impaired lung function received the cysteinyl-leukotriene receptor antagonist ICI 204,219 (40 mg by mouth) and placebo in random order on 2 days at least 1 week apart. The increase in forced expiratory volume in 1 s (FEV1) above baseline was significantly greater after ICI 204,219 than after placebo. This effect persisted after nebulised salbutamol. These findings suggest that cysteinyl-leukotrienes are one of the causes of persistent bronchoconstriction in chronic asthma.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adult
  • Airway Resistance / drug effects
  • Albuterol / administration & dosage
  • Albuterol / therapeutic use
  • Asthma / drug therapy*
  • Asthma / physiopathology
  • Bronchoconstriction / drug effects
  • Double-Blind Method
  • Drug Evaluation
  • Female
  • Forced Expiratory Volume / drug effects
  • Humans
  • Leukotriene Antagonists*
  • Male
  • Middle Aged
  • Tosyl Compounds / therapeutic use*

Substances

  • Leukotriene Antagonists
  • Tosyl Compounds
  • Albuterol
  • zafirlukast